FDA-EMA Pilot Advice Scheme On Complex Generics Sees Slow Uptake

Two Applicants Have Completed The US-EU Parallel Advice Process So Far

While approaching the third year of its launch, the parallel advice program has seen a handful of applicants, but regulators on both sides of the Atlantic remain optimistic.

Tiny people standing on jigsaw puzzle pieces with EU and US flags
The voluntary pilot was launched in 2021 • Source: Shutterstock

A collaborative scheme between the US Food and Drug Administration and the European Medicines Agency is yet to be embraced by complex generic developers. According to the FDA’s latest update on the parallel scientific advice scheme, only two applicants were granted PSA meetings and have completed the process more than two years after its launch.

Based on the preliminary applicant feedback to the program, agencies were recommended to “provide procedural clarifications, clarify program timelines and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

More from Products

MSN Labs Swerves 2026 US Entresto Patent Ahead Of Separate July 15 Expiry

 
• By 

Novartis has filed an immediate appeal after a US district court ruled that MSN Labs would not infringe one of its key patents shielding its $7.8bn Entresto brand, and denied the originator injunctive relief.

UK Sitagliptin Prices Shoot Up In June

 
• By 

Multiple strengths of sitagliptin saw average price increases that topped our rundown of UK generic pricing data in June.

Biocon’s Denosumab Biosimilar Approved In The UK As Competition Grows In Europe

 

Denosumab biosimilar ranks are filling up in Europe as approvals flood in. Yet, little is known about the launch dates.